13F Holdings
中文EN

GNPX Genprex, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1595248 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-1.0%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-233.7%
ROA-160.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets21.7%
Debt / equity0.00x
Current ratio4.26x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-15.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—$0$0$0$0
R&D expense$9.43M$10.54M$17.62M$11.51M$8.97M
SG&A expense$6.09M$10.63M$13.43M$12.30M$11.68M
Operating income-$15.52M-$21.17M-$31.06M-$23.83M-$20.67M
Income tax$0$2,650$0$0—
Net income-$16.23M-$21.11M-$30.86M-$23.74M-$20.66M
EBITDA-$15.52M-$21.17M-$31.04M-$23.81M-$20.65M
EPS (basic)-17.40-266.89-22.56-19.80-0.44
EPS (diluted)————-0.42
Weighted avg. shares (diluted)————47.10M
Balance sheet
Cash & equivalents$7.83M$1.60M$6.74M$20.95M$38.63M
Receivables——$0$34,852$0
Current assets$8.36M$2.08M$7.53M$21.47M$39.14M
PP&E, net$0$0$7,859$23,032$48,608
Intangibles—$0$773,478$702,095$642,360
Total assets$10.16M$4.12M$10.67M$25.09M$42.86M
Current liabilities$2.17M$2.50M$3.25M$2.81M$1.59M
Total liabilities$2.20M$2.50M$3.25M$2.81M$1.59M
Shareholders' equity$7.96M$1.62M$7.42M$22.27M$41.28M
Shares outstanding149,811217,2341.49M1.20M47.87M
Cash flow statement
Operating cash flow-$15.31M-$17.92M-$24.74M-$17.62M-$14.28M
Capital expenditure———$0$31,700
Free cash flow———-$17.62M-$14.32M
Investing cash flow$0$774,644-$71,214-$59,735-$83,796
Financing cash flow$21.54M$12.01M$10.59M$6,426$25.68M
Depreciation & amortization$0$6,693$15,004$25,575$22,534
Stock-based compensation$300,000$3.30M$5.41M$4.73M$5.35M

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.